These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23368651)

  • 21. The pathogenesis of Barrett's metaplasia and the progression to esophageal adenocarcinoma.
    Grotenhuis BA; van Lanschot JJ; Dinjens WN; Wijnhoven BP
    Recent Results Cancer Res; 2010; 182():39-63. PubMed ID: 20676870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux.
    Agarwal B; Swisher SG; Ajani J; Kelly K; Komaki RR; Abu-Hamda E; Correa AM; Roth JA
    Ann Thorac Surg; 2005 May; 79(5):1716-23. PubMed ID: 15854962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.
    Schlottmann F; Molena D; Patti MG
    Updates Surg; 2018 Sep; 70(3):339-342. PubMed ID: 30039277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Carcinogenesis of Barrett's esophagus].
    Endo T; Sugawara N; Shinomura Y
    Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.
    Grady WM; Yu M
    Dig Dis Sci; 2018 Aug; 63(8):2059-2069. PubMed ID: 29766388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors in the development of esophageal adenocarcinoma.
    Pohl H; Wrobel K; Bojarski C; Voderholzer W; Sonnenberg A; Rösch T; Baumgart DC
    Am J Gastroenterol; 2013 Feb; 108(2):200-7. PubMed ID: 23247577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical study of p53, c-erbB-2, and PCNA in barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model.
    Kawaura Y; Tatsuzawa Y; Wakabayashi T; Ikeda N; Matsuda M; Nishihara S
    J Gastroenterol; 2001 Sep; 36(9):595-600. PubMed ID: 11578062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Barrett's esophagus].
    Neuhaus H
    Praxis (Bern 1994); 2004 Nov; 93(47):1951-7. PubMed ID: 15656005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
    Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
    Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From Reflux Esophagitis to Esophageal Adenocarcinoma.
    Souza RF
    Dig Dis; 2016; 34(5):483-90. PubMed ID: 27331918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New strategies in Barrett's esophagus: integrating clonal evolutionary theory with clinical management.
    Reid BJ; Kostadinov R; Maley CC
    Clin Cancer Res; 2011 Jun; 17(11):3512-9. PubMed ID: 21498395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression to cancer in Barrett's esophagus is associated with genomic instability.
    Rabinovitch PS; Reid BJ; Haggitt RC; Norwood TH; Rubin CE
    Lab Invest; 1989 Jan; 60(1):65-71. PubMed ID: 2911184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence.
    Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE
    Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Barrett's esophagus and risk of esophageal adenocarcinoma.
    Cossentino MJ; Wong RK
    Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenocarcinoma in Barrett's esophagus. A clinicopathologic study of 65 cases.
    Streitz JM; Ellis FH; Gibb SP; Balogh K; Watkins E
    Ann Surg; 1991 Feb; 213(2):122-5. PubMed ID: 1992937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
    Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
    Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study.
    Timmer MR; Martinez P; Lau CT; Westra WM; Calpe S; Rygiel AM; Rosmolen WD; Meijer SL; Ten Kate FJ; Dijkgraaf MG; Mallant-Hent RC; Naber AH; van Oijen AH; Baak LC; Scholten P; Böhmer CJ; Fockens P; Maley CC; Graham TA; Bergman JJ; Krishnadath KK
    Gut; 2016 Oct; 65(10):1602-10. PubMed ID: 26104750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical treatment of Barrett's esophagus: 1980-2003.
    Csendes A
    World J Surg; 2004 Mar; 28(3):225-31. PubMed ID: 14961203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular markers and genetics in cancer development.
    Hormi-Carver K; Souza RF
    Surg Oncol Clin N Am; 2009 Jul; 18(3):453-67. PubMed ID: 19500736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.